logo
logo

Proov Raises $9.7M Series A For At-Home Ovulation Testing Platform

Dec 15, 2021•over 3 years ago

Amount Raised

$9.7 Million

Round Type

series a

Software

Description

MFB Fertility, the creator of a suite of at-home pregnancy-related hormone tests, announced a $9.7 million Series A round this week. The round follows several milestones for the company including an FDA premarket approval for a progesterone urine test and the rollout of a mobile app. It also gives the company more fodder to build towards its thesis: that at-home hormone testing can save both time, and stress related to “unexplained” infertility.

Company Information

Company

Proov

About

The petition is in response to American College of Obstetrics and Gynecology guidelines suggesting progesterone therapy only be given to women who have already had miscarriages (the company argues that certain tests could also used as impetus for progesterone therapy). The company is also currently building a supplement platform that would be integrated with the app. Proov was founded in 2018, after Beckley had her own struggles with infertility and miscarriage. Proov has developed an at-home urine test to measure a metabolite of progesterone, PdG.